Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
China channel feed
#ASCO22: A small China biotech player makes its debut at ASCO with promising data on its GPRC5D multiple myeloma drug
4 years ago
Bioregnum
#ASCO22: Legend, J&J say Carvykti holds up past the two-year mark as pair preps for potential second nod
4 years ago
R&D
Cell/Gene Tx
Sequoia China leads $37M infusion into radiopharmaceuticals player setting up shop in China and Belgium
4 years ago
Financing
Startups
House Republicans attack China-only data in FDA submissions, seek new investigation into research inspections
4 years ago
FDA+
As GSK-partnered Covid antibody racks up global sales, Vir axes WuXi deal and grabs back China rights
4 years ago
Deals
Coronavirus
Fujifilm continues its biotech building spree with new facility in China
4 years ago
Pharma
Manufacturing
Chinese pharma giant Hengrui launches new company for globalization play — with a Merck KGaA vet at the helm
4 years ago
Startups
Under-the-radar Chinese biotech scores $47M upfront in secretive Merck deal around cancer drug
4 years ago
Deals
Chinese Alzheimer's drugmaker says lack of funding, Covid outbreak forced it to shutter international PhIII
4 years ago
R&D
Starna Therapeutics emerges with financing for mRNA vaccine and therapies
4 years ago
Financing
Startups
Scoop: Green Valley's seaweed-derived Alzheimer's drug, approved in China, is halted in PhIII study
4 years ago
R&D
Pharma
SEC shines regulatory spotlight on I-Mab, Sinovac and others as more Chinese biotechs scramble to comply with new law
4 years ago
FDA+
Frank Zhang is in the clear after Chinese authorities conclude investigation without charges, company says
4 years ago
People
Law
FDA hits Hutchmed, Junshi drugs with CRLs — further clarifying its stance on China-only data
4 years ago
FDA+
Novartis records another tislelizumab win en route to bringing BeiGene's PD-1 to FDA's doors
4 years ago
R&D
Pharma
Vivo Capital pitches $60M to bring Arrowhead's RNAi meds to China via joint venture
4 years ago
Deals
Following BeiGene, Zai Lab changes auditors amidst SEC threat of delisting
4 years ago
Financing
Federal jury convicts Kansas chem professor on four counts in 'China Initiative' case
4 years ago
Law
Spotting a gem from transpacific biotech, AstraZeneca pays $25M cash to pick up a preclinical bispecific antibody
4 years ago
Deals
After steering made-in-China CAR-T all the way from obscurity to approval, Frank Fan resigns from Legend
4 years ago
People
Cell/Gene Tx
Harvard scientist Charles Lieber seeks acquittal in 'ill-conceived' China Initiative case
4 years ago
People
Law
Most Chinese firms could keep their US listings under draft framework — report
4 years ago
Pharma
Updated: SEC chair denies a deal to prevent Chinese company delisting is close — reports
4 years ago
Pharma
As branded drug sales surge, analysts predict China market will remain 'very attractive'
4 years ago
Pharma
First page
Previous page
10
11
12
13
14
15
16
Next page
Last page